Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Cuba's informal market finds new space on growing internet
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Cuba's informal market finds new space on growing internet
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Cuba's informal market finds new space on growing internet
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Cuba's informal market finds new space on growing internet

3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up

Key Points

  • The billions that will be spent to find a potential cure for Alzheimer's disease presents investors with an opportunity.
  • Biogen has to be considered the leader in the clubhouse with the results from Lecanemab.
  • Eli Lilly is a biotech giant that stands to benefit from the success of Lecanemab as it waits to hear from the FDA about Donanemab.
  • Cassava Sciences is taking a different approach altogether and may turn out to be a big winner for speculative investors. 
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up

Alzheimer’s Disease remains one of the leading causes of death, and yet the nature of the disease makes finding a cure elusive. But that’s not for a lack of effort. A 2021 report by the research firm Research and Markets projects that the worldwide Alzheimer’s market will be worth $9.4 billion by 2027. This presumes a compound annual growth rate of 6.8% between 2020 and 2027.  

Not surprisingly, there are several companies that are involved in developing drugs and therapeutics. And the companies that can successfully bring a solution to the market stand to benefit. This article will look at three names that buy-and-hold investors may want to consider. 

Biogen 

It wasn’t so long ago that Biogen (NASDAQ:BIIB) stock was under pressure after the FDA granted controversial approval of its leading drug candidate, Aducanumab. This came after an advisory panel for the U.S. Food & Drug Administration recommended that Aducanumab not be approved.  

At issue is whether Aducanumab could deliver the hoped-for results. Aducanumab is designed to help reduce amyloid plaques from building up. This is thought to be a leading cause of Alzheimer’s. However, the limited ability of drugs to reduce these plaques has cast some doubt on the role of amyloid plaque in treating Alzheimer’s disease. 


 However, recent Phase 3 results for another Biogen candidate, Lecanemab, delivered encouraging results that are renewing interest in this field of treatment. According to Biogen’s website, Lecanemab “is an antibody that binds to amyloid, which could reduce its presence in the brain and potentially slow the progress of the disease.” 

Biogen is developing the drug in partnership with the Japanese pharmaceutical company Eisai – and profits for Lecanemab will be split 50/50 between the two companies. Investors should also pay attention to Biogen’s extensive pipeline of drugs that are in various stages of clinical trials. 

Eli Lilly 

Eli Lilly (NYSE:LLY) was one of the pioneers in Alzheimer’s research and has sponsored over 70 studies on Alzheimer’s disease and mild cognitive impairment (MCI). The company stands to benefit from the recent results by Lecanemab because its own leading candidate, Donanemab, is designed with the same end goal of reducing the buildup of beta-amyloid plaque.  

The company received a breakthrough therapy designation from the FDA in 2021 which may allow the company to accelerate the time in which Donanemab can get to market. That remains to be seen. Eli Lilly expects to hear back from the FDA sometime in early 2023.  

Another reason to consider LLY stock is that the company is an established firm with many drugs that are commercially available in addition to a deep pipeline. For less risk-tolerant investors this helps take some of the risk away from Eli Lilly as its not dependent on the success of any one candidate. 

Cassava Sciences 

For risk-tolerant investors willing to take a chance on a clinical stage company, Cassava Sciences (NASDAQ:SAVA) presents an intriguing opportunity. As I noted above, the efficacy of drugs to remove amyloid plaque is ongoing. And that means there’s an opportunity for companies that are taking a different approach. 

That’s where Cassava comes in. The company’s research is focusing on the root cause for why the amyloid plaque builds up in the first place. The company’s lead candidate, Simufilam, has shown promising results that in Phase 2 studies. According to the company’s website, “Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain.” 

The drug is currently in Phase 3 clinical trials, and the company hopes to release results by the third quarter of 2023. That means regulatory approval is still some time away. But for investors with a long time horizon, SAVA stock shows some promise.  

 

Should you invest $1,000 in Eli Lilly and right now?

Before you consider Eli Lilly and, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and wasn't on the list.

While Eli Lilly and currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Biogen (BIIB)
2.2168 of 5 stars
$305.15+0.6%N/A15.54Moderate Buy$299.75
Eli Lilly and (LLY)
2.8641 of 5 stars
$365.25+1.0%1.07%54.84Moderate Buy$359.78
Cassava Sciences (SAVA)
1.4878 of 5 stars
$34.92+3.8%N/A-19.62Hold$28.00
Compare These Stocks  Add These Stocks to My Watchlist 

Chris Markoch

About Chris Markoch

Contributing Author: Retirement, Individual Investing

Chris Markoch is a freelance financial copywriter with over five years of experience covering various aspects of the financial markets. You may find his writing a little different than other stock articles you’ve read. And that’s OK with him. Chris doesn’t have a traditional finance background. What he does bring to the table is a strong business and marketing background having worked for agencies that serviced Fortune 500 companies. With that in mind, he isn’t overly impressed with what companies say, and more focused on what they do. And because buyer behavior dictates so much of what happens with a stock, Chris always keeps the end consumer close in mind. Chris has been writing for MarketBeat since 2018.

Contact Chris Markoch via email at CTMarkoch@msn.com.